Heart disease kills more people worldwide than any other illness 1 . Much of this morbidity and mortality occurs because the heart is one of the least regenerative organs in the human body 2 . The ability of cardiomyocytes to proliferate is limited to ~1% per year 3-5 , and it has been difficult to identify a cardiac stem cell population that can give rise to new myocytes at significant levels 3,6 . As a result, cardiac injuries, such as myocardial infarctions, heal by scar formation, and the heart loses contractile ability in direct relation to the muscle deficit. When significant myocardial mass is lost, patients often progress to heart failure. Drug treatments for heart failure manage symptoms but do not address the root problem of muscle deficiency.
contractile function in physiologically relevant large animals. For this we chose the non-human primate Macaca nemestrina because of its evolutionary proximity to humans, the similarity of the two species' cardiovascular systems, and because it is a well-established model in transplantation biology. This model should yield the best possible prediction of the human response to hESC-CM transplantation. The second was to understand the physiological basis for the ventricular arrhythmias induced by hESC-CMs. We report here that hESC-CMs provide robust and durable improvement in cardiac function in the infarcted macaque heart. We also provide evidence that graft-induced arrhythmias result from pacemaker-like activity rather than abnormal conduction.
RESULTS

hESC-CMs improve ventricular function
The central hypothesis of this study was that hESC-CM would remuscularize the hearts of macaque monkeys and restore their function after myocardial infarction. To assess the impact of hESC-CM transplantation on left ventricular structure and function, we developed techniques for cardiac magnetic resonance imaging (MRI) in the macaque. MRI is currently the gold standard for non-invasive imaging of cardiac structure, function, and tissue characterization. It provides reproducible measurements of left ventricular end-diastolic and end-systolic volumes, cardiac output, left ventricular ejection fraction (LVEF), regional wall thickening during systole and infarct size 27, 28 . Our previous study in macaques 25 created infarcts by occluding the distal left anterior descending (LAD) coronary artery for 90 min, followed by reperfusion. Pilot studies showed that this protocol gave a minimal reduction in ejection fraction, from ~65% at baseline to ~60% after infarction. For the functional studies here, we induced larger infarcts by occluding the mid-LAD for 3 h, followed by reperfusion ( Fig. 1a) . This induced transmural infarcts ( Fig. 1b and Supplementary Table 1 ) and reduced ejection fraction to ~40% 2 weeks after infarction ( Fig. 1d,e) , creating a greater window for detecting functional improvement.
With this new infarction protocol in place, we undertook an efficacy study. Electrodes for electrocardiogram (EKG) telemetry were implanted at the time of infarction to assess spontaneous arrhythmias. Immunosuppressive agents were administered starting 5 d before cell delivery (Fig. 1a) . Cells were administered ~14 d post-infarction by direct injection under surgical visualization. Cardiomyocytes were derived from the RUES2 hESC line in monolayer cultures using activin A and BMP4 to induce differentiation 22, 24, 25 , or from the H7 hESC line in suspension cultures using small-molecule Wnt pathway modulation to induce differentiation 29 . The five animals studied by MRI received cardiomyocytes derived from the H7 hESC line. Purity of the cultures averaged 86-99% cardiomyocytes, based on flow cytometry for cardiac troponin T (Supplementary Fig. 1) . We delivered hESC-CM (n = 2) Control (n = 1) Figure 1 Effects of hESC-CM transplantation on cardiac function. (a) Timeline for the efficacy study in which non-human primates received 180 min ischemia and/or reperfusion in the mid-LAD vascular bed. Cardiac MRI is incorporated to measure cardiac dimensions and function. Electrophysiology studies are also included in the protocol to study the cause, inducibility, and severity of the ventricular arrhythmias. (b) A representative stain of a shortaxis cross section of an infarcted non-human primate control heart with picrosirius red and fast green, where the infarct collagen is red and healthy myocardium is green. The infarct is transmural, with sparing of subendocardial myocardium. These experiments were repeated four times for controls and five times for hESC-CM treatment, with similar results. Scale bar, 5 mm. (c) Representative short-axis cine MRI at end-diastolic and end-systolic phases of the cardiac cycle at 4 weeks after treatment (6 weeks after MI). Blood in the chamber appears bright. There is greater ejection of blood in the hESC-CM heart during systole. These experiments were repeated four times for controls and five times for hESC-CM treatment, with similar results. Scale bar, 1 cm. (d) Plot of LVEF for individual subjects (four control animals, blue; five hESC-CM-treated animals, red) before infarction (pre-MI), at the post-infarction baseline (1 d before injection) and at 1 month after treatment. All hESC-CM hearts show significant improvement, while there is minimal improvement in controls. (e) Mean LVEF is comparable between groups before infarction and at post-infarction baseline (P > 0.05, paired t-test, df = 4) but shows a considerable improvement after hESC-CM treatment (*P = 0.004, paired t-test, df = 4). Data are from four biologically independent control animals and five hESC-CM-treated animals. Error bars, mean ± s.e.m. Individual data points are shown in 1 d. NS, not significant. (f) Change in LVEF (∆LVEF) from baseline to 4 weeks is significantly greater in hESC-CM hearts than in controls. Data are from four biologically independent control animals and five hESC-CM-treated animals. Error bars, mean ± s.e.m. (*P = 0.004, two-tailed t-test, df = 7). (g) There is a variable trend (P = 0.135, paired t-test, df = 7) toward increased systolic thickening of the infarcted wall in hESC-CM-treated animals. Data are from four biologically independent control animals and five hESC-CM-treated animals. Error bars, mean ± s.e.m. (h) Extending survival to 12 weeks demonstrates a modest reduction in LVEF in control hearts and further improvement with hESC-CM treatment. This indicates the benefits seen at 4 weeks are stable with the potential for substantial further improvement.
A r t i c l e s 750 million hESC-CMs or vehicle (RPMI media/pro-survival cocktail (PSC)) by surgically exposing the heart and injecting the cells intramuscularly into the infarct region and the border zones. MRI was performed 1 d before cell delivery and ~27 d after cell delivery, with all scans independently evaluated by three blinded observers. A subset of the animals underwent catheter-based electrophysiological studies at approximately day 14. Most macaques were euthanized ~28 d after cell transplantation, with the exception of two hESC-CM-treated and one control animal, which were given prolonged immunosuppression and studied by MRI at 12 weeks post-injection to assess the durability of the functional effects.
Seventeen macaques were initially enrolled in this study without randomization, and another two were enrolled for targeted mechanistic studies, described below. Eight animals were excluded from final MRI analysis due to protocol design or complications outlined in Supplementary Figure 2 , only one of which was related to cell treatment, but nine successfully completed the infarction, cell, or vehicle injection, and multiple MRI scans ( Fig. 1c) . MRI scans were read by two blinded observers, with low interobserver variability ( Supplementary Fig. 3a ).
Prior to infarction, LVEF was 69.8 ± 1.3% in the control group and 68.8 ± 2.1% in the hESC-CM group ( Fig. 1d,e ; P > 0.4, NS). After infarction but before treatment, both groups exhibited similarly depressed LVEF, averaging 38.0 ± 2.3% in control animals and 39.4 ± 2.1% in hESC-CM-treated animals (P > 0.67, NS). At 4 weeks posttreatment, transplantation of hESC-CMs significantly improved LVEF (hESC-CM vs. control: 50.0 ± 1.9 vs. 40.5 ± 2.2%, P < 0.05; Fig. 1d,e ). The effects of hESC-CM transplantation also could be seen by comparing the change in LVEF between day −1 and day 27: the control group showed an improvement of 2.5 ± 0.8%, whereas the hESC-CM-treated group improved by 10.6 ± 0.9% (P = 0.001; Fig. 1f ). To assess contractile function in the infarct zone, we measured systolic wall thickening. Prior to therapy, all animals had 0% systolic LV wall thickening in the infarct zone, and all control hearts had 0% systolic LV wall thickening at 4 weeks. In contrast, after hESC-CM transplantation, wall thickening in the infarct improved to 22.0 ± 12% of the LV wall ( Fig. 1g) . However, because the improvement ranged from 0-67%, this was not statistically significant. Wall thickening in the non-infarcted region was not different between these two groups at any time ( Supplementary Fig. 4) , and there was no significant effect of cardiomyocyte transplantation on left ventricular end-diastolic volume. Taken together, these data indicate that formation of human myocardium in the infarcted non-human primate heart improves LV systolic function.
To test for the durability of the functional benefit, we studied three macaques at 3 months post-engraftment (two treated, one control; Fig. 1h ). In the control animal, the LVEF decreased from 43.9% at day 27 to 40.4% at 3 months. In the hESC-CM-treated animals, LVEF improved from 51.1% and 51.0% at day 27 to 66.0% and 61.0% at 3 months. Thus, the benefit from hESC-CM therapy appears to be durable for 3 months, with function improving between 1 and 3 months.
Ventricular arrhythmia analysis
To study spontaneous arrhythmias, we outfitted macaques that had received 3-h coronary occlusion followed by reperfusion with EKG telemetry systems. Cardiac rhythms were recorded continuously for 24-h periods at 3-d intervals, and episodes of sustained ventricular tachycardia or accelerated idioventricular rhythm were quantified by one observer and validated by a second ( Supplementary Fig. 3b and Fig. 2a-d) . A total of six hESC-CM-treated and four control animals successfully completed this phase of the study. Arrhythmias were quantified in hours/day and are shown for each animal in Figure 2e ,f. Compared to our previous study using the small infarct model with amiodarone anti-arrhythmic treatment 25 , there were two notable differences. First, both groups showed significantly (P = 0.004) more arrhythmias before cell and/or vehicle injection. This could be due either to the larger infarcts or the omission of the amiodarone from the current study. Second, unlike the small infarct model, where cell-treated animals had more frequent arrhythmias than controls, there was no statistical difference in the number or duration of arrhythmias between the two groups either before or after injection.
The telemetry data were highly variable, however, and one macaque deserves individual mention. This cell-treated animal developed extensive ventricular arrhythmias, including both ventricular tachycardia and accelerated idioventricular rhythm (AIVR). The ventricular arrhythmias began 10 d after cell injection and largely consisted of continuous (>20 h/day), monomorphic, wide complex tachycardia and AIVR ( Fig. 2f, arrow) . Although the animal was not in acute distress at any time, these arrhythmias were of sufficient severity that adequate MRI scans for functional studies were unattainable due to the high rate and irregularity. An arrhythmia of this duration was not observed in the control group. Despite the lack of statistical proof, we think that the most prudent interpretation is that one of the six cell-treated animals developed arrhythmias that likely were due to the hESC-CM graft.
The lower burden of engraftment arrhythmia in the current study could result from differences in the infarct model (large infarcts here), the cells (transgenic cells expressing the Ca 2+ indicator GCaMP3 were used previously), or from unanticipated effects of the anti-arrhythmic drug, amiodarone 30 , used previously. We therefore returned to the small infarct model and transplanted transgene-free cardiomyocytes and omitted amiodarone (N = 1 each; Supplementary Fig. 5 ). The transgene-free and amiodarone-free animals experienced a high burden of ventricular arrhythmias, providing evidence that the lower burden of arrhythmias in this study resulted from the larger infarcts.
To further characterize the ventricular arrhythmias and to assess arrhythmia vulnerability, we performed catheter-based electrophysiology studies using the CARTO III mapping system. Electrophysiology studies included programmed ventricular stimulation to induce arrhythmias, as well as activation and voltage mapping to characterize induced and spontaneous ventricular arrhythmias. We employed a standard, programmed, ventricular-stimulation protocol, where a series of entrainment stimuli were followed by up to three extra stimuli, delivered in succession at coupling intervals down to the ventricular refractory period, with or without isoproterenol infusion. Arrhythmia inducibility and severity were graded as previously reported 31 . The proposed mechanism of the tachycardia was determined by electrophysiological features including cycle length stability, pacing inducibility, and susceptibility to pace or electrical cardioversion. In instances where there was spontaneous initiation, significant cycle length variation without change in ventricular tachycardia morphology, and the inability to pace-induce or terminate with pacing or electrical cardioversion, the mechanism was presumed to be enhanced automaticity. In contrast, a relatively fixed cycle length and the ability to pace-induce, and susceptibility to pace or electrical cardioversion suggested a reentry mechanism.
Twelve electrophysiology studies were performed on eight animals (three control and five hESC-CM treated; one of the hESC-CM animals was from the small infarct protocol; Supplementary Fig. 2 ). Ten studies on eight animals yielded data on arrhythmia inducibility. In four of these (three hESC-CM treated, one control), ventricular stimulation resulted in induction of only brief episodes of non-sustained A r t i c l e s ventricular tachycardia and were thus unable to be mapped. In two electrophysiology studies (one control and one hESC-CM-treated), we induced ventricular tachycardia that caused considerable hypotension, which precluded activation mapping and required termination of the arrhythmia with DC cardioversion. Quantitatively, there was no significant difference in arrhythmia inducibility between the vehicle-injected and hESC-CM-injected hearts ( Fig. 2g) . Similarly, the severity of the induced arrhythmias did not differ between the hESC-CM-treated and control animals ( Fig. 2g) . Thus, intramyocardial injection of hESC-CMs did not increase the risk and the severity of inducible ventricular arrhythmias.
Activation maps of ventricular tachycardia were obtained in two hESC-CM-treated and one control animal ( Fig. 2h,i) . In all cases, the ventricular tachycardia originated from a focal region. The control animal was studied twice, at 2 and 4 weeks post-injection, and in both studies the VT was induced, not spontaneous. In both studies the VT origin mapped to the low-voltage scar zone. The VT in the control heart was induced by pacing and could be terminated by overdrive pacing, both of which point to micro-reentry as the mechanism. Both cell-treated animals had spontaneous ventricular tachycardia when arrhythmia mapping began. These hearts could readily be overdrivepaced to 300 beats/min, but upon cessation of pacing, they returned almost immediately to their baseline tachycardic rates. We attempted to correct the arrhythmias with electrical cardioversion, but in both instances, after a brief pause the rhythm resumed at its previous rapid rate. Taken together, these data suggest the arrhythmias in control hearts arise from a small focus of reentry, whereas those in the hESC-CM have features of abnormal impulse generation.
Tumor survey and structural analysis One potential complication of hESC-CM therapy is teratoma formation or ectopic tissue growth 32 . All animals underwent a full necropsy by an experienced primate pathologist with a detailed gross and microscopic examination of the brain and all thoracic and abdominal organs. One cell-treated monkey had a microscopic focus of carcinoma in one kidney that was contained within small lymphatic and venous channels ( Supplementary Fig. 6a,b) . To test whether this tumor was of human or macaque origin, we performed in situ hybridization for human pan-centromeric genomic DNA sequences, and we also extracted DNA from the paraffin section for PCR genotyping. The tumor did not hybridize with the human-specific probe, and PCR detected only macaque DNA and was negative for human DNA ( Supplementary  Fig. 6c-f ). This indicates that the tumor was of macaque origin. By immunohistochemistry, the tumor was negative for thyroid transcription factor-1 and GATA3. Conversely, it showed uniform, strong nuclear staining for Pax8. This immunophenotype is most consistent with a renal cell carcinoma 33 . No teratomas were detected in any animal, and no other atypical cellular masses were identified. (e,f) Spontaneous ventricular arrhythmias in large infarct protocol (3-h mid-LAD occlusion) for four biologically independent control animals (e) and five biologically independent hESC-CM-treated animals (f) were recorded as h/d (24 h). Both groups have ventricular arrhythmias before and after injection (day 0), but the hESC-CM group had one subject with protracted arrhythmias (arrow), that likely are treatment-related. (g) Programmed electrical stimulation studies demonstrate that the inducibility and severity between biologically independent control (N = 3) and hESC-CM-treated hearts (N = 5) were not significantly different (P = 0.816, two-tailed t-test, df = 6 for inducibility; P = 0.411, two-tailed t-test, df = 6 for severity). Group data indicate mean ± s.e.m. (h,i) Electrical activation maps acquired using an endocardial catheter electrode. Red, early activation; magenta, late activation. (h) Activation in a non-infarcted macaque heart initiates at the apex (red; pointing toward the observer) and spreads toward the base. N = 1. (i) Activation map from an hESC-CM-engrafted heart during spontaneous ventricular tachycardia, with apex pointing toward lower right. Activation originates from an apparent point source in the anterior septum. No rotor was identified. This experiment was independently repeated twice with similar results.
A r t i c l e s
Histological analyses showed that infarcts in the sham-injected hearts averaged 23.6 ± 2.0% of the LV mass, whereas 19.9 ± 1.1% of the LV was infarcted in hESC-CM-treated hearts ( Fig. 3a ; P = 0.18, NS). We were able to obtain paired measurements of infarct size in three control and five hESC-CM-treated hearts at baseline and at 4 weeks post-engraftment using delayed gadolinium-enhanced MRI ( Fig. 3b and Supplementary Fig. 7 ). This showed greater scar shrinkage in the hESC-CM-engrafted infarcts (5.3 ± 0.2% vs. 2.3 ± 0.9% of the LV; P < 0.05). This implies that the original infarct size was 25.9% of the LV in controls and 25.2% of the LV in hESC-CM-treated hearts.
To specifically label wild-type hESC-CMs in the graft, we identified two monoclonal antibodies to human grafts in the primate heart. The cardiac troponin I (cTnI) antibody is human-specific, and the slow-skeletal troponin I (ssTnI) antibody recognizes the relatively immature human cells that still express this developmentally regulated isoform 34 . In archival hearts that had received GFP-expressing cardiomyocytes, these troponin antibodies labeled regions identical to those identified by immunostaining for GFP or via in situ hybridization for human pan-centromeric sequences ( Supplementary  Fig. 8 ). There was virtually no staining of macaque cardiomyocytes with either antibody. One macaque damaged its intravenous catheter, resulting in interruption of immunosuppression at 5 weeks post-transplantation in a planned 3-month survival protocol. No graft was detected in this animal, presumably due to rejection, and it was excluded from graft size calculations. In all other animals, large grafts of human myocardium were readily identified. Grafts ranged from 5.7-15.6% of the infarct (11.6 ± 2.3%; Fig. 3d ) and 1.1-3.4% of the LV (2.2 ± 0.7%; Fig. 3c ). In control hearts the infarct was a transmural scar, with subendocardial sparing of the host myocardium and considerable wall thinning ( Fig. 3f) . In hESC-CM hearts, large grafts were readily identified, often measuring more than a centimeter in greatest dimension ( Fig. 3g ). Grafts were located in the central infarct region and in the border zone myocardium, suggesting little migration occurred from the original injection sites ( Supplementary  Fig. 9 ). We estimated the number of cardiomyocytes in the grafts using histomorphometry ( Fig. 3e) . At 4 weeks post-injection there were 21.7 and 83.9 million cardiomyocytes in the grafts. At 3 months there were 109 and 126 million cardiomyocytes in the grafts, suggesting expansion due to proliferation.
At 4 weeks post-engraftment, 90% of graft cells were definitive ventricular cardiomyocytes (MLC2v + /MLC2a − ; Fig. 3h-j) , and 10% typed as either atrial, sinoatrial, or immature ventricular cardiomyocytes A r t i c l e s (MLC2a + /MLC2v − ); only rare double-positive cells were identified. By 3 months post-transplantation, 99% of graft cells were MLC2v + , with <1% still expressing MLC2a. This indicates that the vast majority of cardiomyocytes generated by the differentiation protocol used in this study adopted a ventricular phenotype after transplantation, although expression of MLC2v is time-dependent. Cardiomyocyte grafts showed considerable maturation in vivo. At 4 weeks post-transplantation (Fig. 4a ) the cardiomyocytes were relatively small, had myofibrils principally at the cell periphery, and their alignment was disheveled. Additionally, the junctional proteins N-cadherin and connexin43 were distributed circumferentially ( Supplementary Fig. 10) . At 3 months, the cardiomyocytes were larger, had myofibrils throughout the cytoplasm, and were better aligned ( Fig. 4b) . N-cadherin was often polarized to intercalated disklike structures, whereas connexin43 remained distributed circumferentially, though to a lesser extent than at 4 weeks ( Supplementary  Fig. 10 ). Additionally, by 3 months the hESC-CMs had readily discernible caveolin 3 + invaginations of the sarcolemma that likely represent T-tubule networks (Fig. 4c) . Although relatively immature, the 4-week grafts already had begun switching from the fetal ssTnI to the adult cTnI isoforms (Fig. 4a) . Increased intensity of cTnI staining was readily apparent at 3 months ( Fig. 4b) , again indicating maturation. Areas of electromechanical integration were readily identified in all hearts where hESC-CMs formed N-cadherin + adherens junctions and connexin43 + gap junctions with host cardiomyocytes (Fig. 4d-g) .
Grafts had an extensive network of CD31 + blood vessels (Fig. 4h,i) , indicating vascularization by the host coronary circulation. At 4 weeks, grafts averaged 406 ± 11 vessels/mm 2 , and this increased to 576 ± 4 vessels/mm 2 at 3 months, likely reflecting ongoing angiogenesis. In contrast, the infarct scar around the graft showed a timedependent decline in vascular density, from 450 ± 40 vessels/mm 2 at 4 weeks to 284 ± 58 vessels/mm 2 at 3 months. Vascular density in the remote myocardium did not change over time, averaging 1,034 ± 1.2 and 1,043 ± 2.5 vessels/mm 2 at 4 weeks and 3 months, respectively.
Graft cardiomyocyte proliferation was measured by double staining for pericentriolar material-1 (PCM-1) and Ki67. PCM-1 marks the outer perimeter of cardiomyocyte nuclei 35 , and Ki67 is a pancell-cycle epitope. Graft cell proliferation was detected in all hearts (Fig. 4j,k) . At 4 weeks, graft cardiomyocyte proliferation rates were 10.3% and 3.5%. At 12 weeks, the proliferation rates were 2.6% and 3.5%. This demonstrates that considerable cell cycle activity occurs in the grafted cardiomyocytes, and coupled with the measured increase in graft cell number between 4 and 12 weeks, suggests that these are complete cell divisions rather than increases in ploidy.
The large size of these grafts made visualization by cardiac MRI possible. Using delayed gadolinium enhancement, three animals showed the appearance of islands of new tissue (viable Gd-negative tissue) within the infarcted anterior wall and septum at 1 and 3 months after treatment (Fig. 5a-c) . These islands were ~1 cm in maximal dimension. By carefully cross-registering histology and MRI scans, we identified regions of human myocardium, >1 cm in maximal dimension, that corresponded to these Gd-negative regions in the MRI images ( Fig. 5d,e ). Masses of this size are easily visualized by MRI, leading us to conclude that it is possible to image large-scale regeneration from hESC-CM grafts.
DISCUSSION
A long-term goal of our program is to remuscularize the heart after myocardial infarction, and thereby improve its function. We have shown here that hESC-CMs can remuscularize infarcts in macaque monkey hearts and, in so doing, reduce scar size and restore significant levels of cardiac function. The infarcts studied were large, reducing ejection fraction from 69% to ~40%. No significant spontaneous recovery occurred in the vehicle-injected group (~2.5%), whereas all hESC-CM-treated hearts showed significant recovery at 4 weeks (10.6 ± 0.9%). Based on studies on three macaques extending to 3 months, the benefit to cardiac function appears durable, with further functional improvement between 1 and 3 months. Although pluripotent stem cell derivatives can cause teratomas 32, 36, 37 , none were observed in the current study.
The 20% absolute improvement in LVEF seen in the two hESC-CM hearts studied at 3 months was striking and shows that substantial mechanical improvement can occur between 1 and 3 months. Histological section corresponding to the region boxed in c, stained with picrosirius red to identify collagen and fast green to identify myocardium. Infarct scar is readily identifiable as red tissue, but it contains islands of green tissue consistent with myocardium. Scale bar, 5 mm. (e) Adjacent section from region boxed in c stained for human cTnT (brown) to identify human myocardial graft. There is extensive human myocardium within the infarct and in the lateral border zone, measuring >1 cm in maximal dimension. Note that human myocardium within the scar would be visible by MRI, but grafts in the border zone host myocardium would be MRIinvisible, since both exclude Gd. This experiment was repeated four times with biologically independent hESC-CM-treated animals, with similar results found in three. In one animal, the graft could not reliably be distinguished by MRI.
A r t i c l e s Shiba et al. 26 also found significant improvement in LVEF after transplantation of allogeneic macaque induced pluripotent stem cell (iPSC)-derived cardiomyocytes into macaque infarcts 26 . The mechanical benefit could, in principle, result from direct mechanical force from the graft and/or paracrine signals 38 that enhance function of the host myocardium. We have shown that hESC-CM grafts form gap junctions with host myocardium and beat in synchrony in rat, guinea pig, and primate hearts 24, 25, 39 . The fact that grafts in the present study are large and beat in synchrony with host myocardium is consistent with a direct graft contribution to contractile function, as are the increased hypertrophy and maturation of engrafted cardiomyocytes. There also is evidence for paracrine effects of human pluripotent stem cell derivatives in the heart. Zhu et al. 40 recently reported that hESC-derived cardiac progenitors enhanced function of non-human primate hearts, even though the cells were rejected. That study differed from ours in many ways, including giving progenitors instead of definitive cardiomyocytes, using a dose that was ~1% of ours, delivering cells immediately after a permanent coronary occlusion instead of 2 weeks after ischemia reperfusion, and using an immunosuppression regimen that did not prevent rejection. Tachibana et al. 41 found that hESC-and hiPSC-derived cardiomyocytes could enhance function of the infarcted mouse heart with minimal engraftment, and they also attributed this benefit to paracrine signaling. These two papers demonstrate that human cardiac progenitors and cardiomyocytes can have benefits through indirect, paracrine mechanisms.
A major goal of this study was to understand the basis for ventricular arrhythmias associated with human cardiomyocyte engraftment. Mouse ESC-derived cardiomyocytes, grafted into the infarcted mouse heart, led to increased spontaneous arrhythmias 42, 43 , yet decreased susceptibility to pacing-induced arrhythmias 44 . When human ESC-CMs were transplanted into injured guinea pig hearts, our group found no effects on spontaneous arrhythmias and reduced susceptibility to pacing-induced arrhythmias 24 . In contrast, hESC-CMs transplanted into the hearts of macaque monkeys with small infarcts induced transient ventricular arrhythmias 25, 45 . Similar arrhythmias were noted when allogeneic monkey iPSC-derived cardiomyocytes were transplanted into infarcted monkey hearts 26 . The similarity of arrhythmias in that allogeneic model and our xenogenic model suggests that species incompatibility is not the basis for arrhythmias in our model.
Although graft-induced arrhythmias appear to be less frequent in the large infarct model used here, at least one of our cell-treated macaques experienced ventricular arrhythmias that can reasonably be attributed to the graft. This raises the possibility that similar arrhythmias could occur in humans treated using the same protocol. We systematically ruled out effects from the GCaMP transgene and the amiodarone drug treatment used in our previous study. Although we hypothesized that hESC-CM grafts were creating tracts of slow conduction leading to reentrant arrhythmias, this was not supported by the data. In electrical mapping studies, no reentrant pathway could be identified; rather, the impulse appeared to originate from a point source in the graft region. This indicates either an ectopic activation source or a reentry pathway smaller than the resolution of our mapping (~1 cm). The arrhythmia could not be extinguished either by overdrive pacing or by electrical cardioversion, both of which favor ectopic impulse generation. Finally, there was no difference in susceptibility of the engrafted hearts versus the vehicle-injected hearts to arrhythmias induced by programmed electrical stimulation, which typically elicits reentrant arrhythmias in regions of abnormal conduction. All these characteristics point toward a disorder of impulse generation (either pacemaking or after depolarizations) rather than reentry as the underlying cause for hESC-CM-induced arrhythmias. These insights may help identify pharmacological or cell-autonomous interventions to limit arrhythmias in the future.
There are several limitations to this study. First, because it is a primate study, group sizes are smaller than is typical for a small animal study. Although we demonstrate statistically robust data for mechanical improvement, some experiments showed trends that would require larger groups for statistical significance. This is mitigated in part by the high animal-to-animal consistency in physiological responses. Second, this xenotransplantation study does not address the human immune response to allogeneic cardiomyocytes. While testing human cardiomyocytes is essential for regulatory approval, allogeneic data from monkeys would be useful.
The functional recovery seen in the current study was larger than we have observed using rat 22 or guinea pig 24 models of myocardial infarction, even though grafts occupied a similar fraction of the ventricle. This finding is likely explained by the greater physiological match between human and macaque. The therapeutic effect may be further augmented when human cardiomyocytes are transplanted into diseased human hearts.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METHODS
Animal care. General features of primate care following infarction and cell therapy (see also Supplementary Notes).
Post-infarct animals were monitored daily with particular attention paid to signs of distress, which may indicate post-procedure pain or symptoms of heart failure. If necessary, furosemide was injected to relieve limb edema or pulmonary congestion, manifest as increased respiratory rate and crackles on auscultation of the chest. Dobutamine infusion was started for clinical signs of poor end-organ perfusion in the setting of heart failure or cardiogenic shock. In the event of frequent PVCs or AIVR on telemetry, a short course of lidocaine infusion was given. For any hemodynamically unstable arrhythmias, the animals would undergo the normal algorithm of advanced cardiovascular life support.
Surgical wounds were carefully examined for signs of infection. In the event of possible infection, wound swabs were obtained and sent for microbiology with the commencement of empirical antibiotics in consultation with veterinary staff. If there were any severe complications noted in the animal, we consulted the veterinarian staffs and treated as clinically appropriate. If the clinical or attending veterinarian diagnosed an untreatable complication, the animal was euthanized. All animals had full necropsies performed by an experienced primate pathologist.
Cell preparation. These studies were approved by the University of Washington Stem Cell Research Oversight Committee. Two lines of hESCs were used in this study. RUES2 cells (obtained from Rockefeller University) were expanded in monolayers in mouse embryonic fibroblast-conditioned medium. Differentiation was performed by replating the cells in high-density monolayers, followed by sequential treatment with recombinant human activin A and BMP4, as previously described 22, 24, 25, 46 . Prior to cryopreservation, RUES2-derived cardiomyocytes were heat-shocked and treated with a prosurvival cocktail to enhance their survival after transplantation 22, 25, 46 . H7 hESCs (obtained from WiCell) were cultured, expanded, and differentiated in suspension-culture format by collaborators at the Center for Applied Technology Development at the City of Hope in California 29 . Pluripotent H7 cultures were expanded in the commercially available media, StemPro hESC SFM. For cardiac differentiation, pluripotent aggregates were cultured in RPMI-1640 supplemented with B-27 (with or without insulin). Differentiation is induced by treatment with the small molecules Chir99021 and IWP-4. On day 21 of differentiation, cardiomyocyte aggregates were dissociated by treatment with Liberase TH and TrypLE. Dissociated cardiomyocytes were cryopreserved in CryoStor CS10 supplemented with 10 µM Y-27632 with freezing performed in a controlled-rate liquid nitrogen freezer. Four lots of H7cardiomyocytes were received by dry-ice shipment, and stored in LN2 before use. Two lots of cardiomyocytes were thawed and blended in approximately equal numbers to produce consistent cell treatments for each of the five treated animals completing the study. Per the City of Hope Product Summary, cryopreserved cells and thawed cells averaged 96% cTnT positive and 85% viable. Following shipment and additional storage time, thawed cells were shown to be 86% viable using an NC200/ Via1-cassette (Chemometec, Denmark) and 87% cTnT positive (human IgG anti-cardiac troponin clone REA400; Miltenyi, Germany).
Approximately 3 h before transplantation, cryopreserved cardiomyocytes were thawed in a 37 °C water bath (2 min ± 30 s). RPMI-1640 supplemented with B-27 and ≥200 Kunitz Units/mL DNase I was added to the cell suspension to dilute the cryopreservation media. Subsequent wash steps were done using RPMI-1640 basal media in progressively smaller volumes in order to concentrate the cell suspension.
Before the last centrifugation step, the cell pellet was resuspended in a 5-factor Pro-Survival Cocktail (PSC). PSC consists of RPMI-1640 basal media supplemented with: 10 µM ZVAD-FMK/Caspase Inhibitor (Calbiochem/ EMD-Millipore); 50 nM TAT-BH4 / BCL-XL (Calbiochem/EMD-Millipore); 200 nM Cyclosporine A (Sandimmune/Novartis); 5 0 µM Pinacidil (Sigma); and 100 ng/ml IGF-1 (Peprotech). Unlike many of our previous studies, no Matrigel was used to deliver the cells.
After resuspension in PSC, the cell suspension was centrifuged so that sufficient volume of PSC supernatant could be removed in order to achieve a target cell density for injection (~7.5 × 10 8 cells in ~1.5 mL PSC). The final volume of the cell suspension was determined by the results of a count sampled before the final centrifugation step. Note that our previous study counted cells before the freezing step. Because there is a 25% cell loss after the thaw, this dose of 750 million cells is comparable to our previously reported dose of 1 billion 25 .
Animal models. All procedures complied with and were approved by the University of Washington Animal Care and Use Committee.
Non-human primate catheterization and surgery. Macaca nemestrina monkeys of either sex, weighing 5.2-12.6 kg, were obtained from the Washington National Primate Center. Ages are specified in Table 1 . Macaques first underwent a 2-to 4-week period of acclimation and training to wear a mesh jacket with an exteriorized line that attached to a tether system to prevent removal of intravenous (i.v.) catheter and EKG electrodes. For all major surgeries and procedures, macaques were sedated with ketamine and propofol, intubated, and ventilated using sevoflurane or isoflurane to maintain anesthesia. Buprenorphine SR was administered to provide perioperative and postoperative pain relief.
Before myocardial infarction creation, an i.v. lidocaine bolus of 1 mg/kg and an infusion of 20 µg/kg/min were used to prevent ventricular arrhythmias. Heparin was delivered i.v. to maintain activated clotting times (ACT) of 250-350 s to prevent thrombus formation. Femoral artery access was obtained via direct cutdown followed by puncture with a 5F Terumo Glidesheath. Under fluoroscopic guidance (OEC 9800 Plus, GE Medical Systems), a 5F Convey guiding catheter (a modified FL3, Boston Scientific) was used to engage the left main coronary artery. A coronary guide wire and angioplasty balloon (Apex 2 × 8 mm PTCA Dilatation Catheter, Boston Scientific) were passed into the midleft anterior descending artery (LAD). The balloon was inflated until the artery was occluded (as demonstrated by angiography) and left inflated for 180 min. Myocardial ischemia was confirmed by ST-segment elevation on EKG.
For telemetric monitoring, tunneled subcutaneous EKG electrodes were implanted (two in the chest wall and one in the abdomen; lead II equivalent) and connected to wireless Vetcheck modules (Vmed Technology) through the jacket/tether system. Dual lumen venous catheters were implanted and tunneled to allow peripheral blood sampling and intravenous drug administration with minimal distress to the animals. Immune suppression was achieved with three drugs. Methylprednisolone was given i.v. 30 mg/kg on the day before hESC-CM delivery, followed by maintenance doses of 6 mg/kg for 2 d, and then 3 mg/kg thereafter until monkeys were euthanized. Cyclosporine A was given i.v. to maintain serum trough levels of 200-250 µg/L from 5 d before hESC-CM delivery until macaques were euthanized. Finally, Abatacept (CTLA4-Ig) 12.5 mg/kg was administered subcutaneously on the day before hESC-CM and every 2 weeks thereafter. Ceftazidime, cefazolin, vancomycin, gentamycin, fluconazole, and acyclovir were administered for prophylaxis of opportunistic infections.
On approximately day 14 after myocardial infarction, macaques were anaesthetized and underwent left-sided thoracotomy. The heart was exposed and a pericardial cradle created. The infarct region was directly visualized, and hESC-CMs were delivered from an epicardial approach into the infarct and peri-infarct region via 15 injections each of 100 µl volume. Needle tips were placed within a preformed mattress suture, and the suture was cinched around the needle to facilitate cell retention. Three injections were delivered via the same epicardial puncture, changing the trajectory of the needle for each. The needle was carefully withdrawn and the mattress suture ligated. For control macaques, an equal volume of PSC vehicle was injected in the same manner as for hESC-CM delivery. Three injections were placed in the peri-infarct border zone, and two were placed into the central ischemic region. LAD coronary occlusion infarcts both the anterior free wall and the anterior 2/3 of the interventricular septum. Although the free wall is readily accessed from an epicardial approach, the septal wall is not visible. We targeted cells to the septum by passing the needle under the LAD artery and inferring the septal wall's location from the curvature of the left ventricular free wall.
Animals were regularly monitored by laboratory and Primate Center staff. Euthanasia was induced under deep anesthesia by i.v. injection of saturated KCl. Control and cell-treatment groups were allocated in an unblinded and non-randomized manner.
Post-surgery care. Post-infarct animals were monitored daily with particular attention paid to signs of distress, which may indicate post-procedure pain or symptoms of heart failure. If necessary, furosemide was injected to relieve pulmonary congestion or limb edema. Signs of distress, such as increased respiratory rate and crackles on auscultation of the chest were used to assess signs of pulmonary congestion. Surgical wounds were carefully examined for signs of infection. In the event of possible infection, wound swabs were obtained and sent for microbiology with the commencement of empirical antibiotics in consultation with veterinary staff. If there were any severe complications noted in the animal, we consulted the veterinarian staffs and treated as clinically appropriate. If the clinical or attending veterinarian diagnosed an untreatable complication (lower extremity ischemia, renal and liver failure, femoral artery dissection), the animal was euthanized. All animals had full necropsies performed by an experienced primate pathologist. Individual procedure notes for each animal are available in the Supplementary Procedures. Cardiac MRI. Cardiac MRI was performed before cell injection (2 weeks after MI) and at 4 and 12 weeks post cell-injection. In vivo imaging studies were conducted on a 3-Tesla Achieva clinical scanner (Philips, Best, Netherlands). Depending on the animal size, two overlapped Flex-M and Flex-L coils (dualelement, approximately 15 and 20 cm diameter, respectively) or an 8-element knee coil was used. Pediatric EKG leads were used for gating of MRI acquisitions. EKG, respiration rate, and arterial oxygen saturation, and body temperature was monitored continuously.
The cardiac MRI protocol included cine imaging for assessment for the LV geometry, global LV contractile function, regional systolic LV wall thickening and delayed gadolinium-enhanced imaging for assessment of the infarct size. Cine images were acquired with an RF-spoiled turbo field echo (T 1 -TFE) sequence that generated 25-30 cardiac phases for 10-12 short-axis slices spanning the left ventricle. Acquisition parameters included a repetition time (TR) 3.9 msec, echo time (TE) 1.9 msec, a 15° flip angle (FA), 4 mm slice thickness (no gap), field of view (FOV) 120 × 120 mm 2 , 1 mm 2 voxel size, 6-8 signal averages, retrospective EKG gating without breath hold.
Animals subsequently received an intravenous bolus injection of gadolinium-based contrast agent ProHance (Bracco Diagnostics Inc., Princeton, NJ) 0.2 mmol/kg, followed by a saline flush. At approximately 8 min after injection, inversion time (TI)-scout images were acquired for determination of TI to null signal from non-infarcted myocardium. At 9 min post-injection of contrast agent, phase-sensitive inversion recovery (PSIR) multislice images were acquired at the LV short axis to visualize the infarct: TR/TE 7.3/3.5 msec, FA 25°, voxel size 1.3 mm 2 , FOV 150 × 150 mm 2 , slice thickness 4 mm without gap, four averages. This was repeated in the long axis plane. Inversion time ranged from 280-350 msec, adjusted by the operator based on TI-scout values. Signal intensity threshold to differentiate normal myocardium from scar was set as ′Full Width Half Max′.
All MRI scans were analyzed by three independent reviewers who were blinded as to treatment and timing of the evaluations. Inter-observer variability was good, with an intraclass correlation coefficient of the average LVEF measurements was 0.978 (95% confidence interval (CI): 0.951-0.990, P < 0.001; Supplementary Fig. 3a,b) . Because within-reviewer variance was lower than the pooled variance, quantitative data from a single reviewer (AN) were used for all figures and tables. Pooled vs. single-reviewer analysis had no impact on statistical significance or the overall magnitude of changes observed. Global LV contractile function and regional wall thickness data were computed from the short-axis cine images. LV endocardial boundaries were traced at end-diastole and end-systole using standard cardiac analysis software (Intellispace Portal, Philips, Best, Netherlands) to obtain end-systolic, end-diastolic volume, LV myocardial mass (LVmass), stroke volume (difference between end-diastolic and end-systolic volumes), cardiac output (CO), and LV ejection fraction (LVEF). LVEF was calculated as the ratio of stroke volume to end-diastolic volume. Papillary muscles were excluded from the volume calculations. Left ventricle wall thickening (LVTh) was calculated as relative difference in LV wall thickness in end-systole and end-diastole, divided by end-diastolic thickness. LVTh was evaluated at the infarcted and non-infarcted areas of the each slice of the heart. Infarct size was calculated from delayed Gd-enhanced images and presented as the ratio of scar area to total LV area.
Echocardiography. Baseline transthoracic echocardiography was performed before infarct surgery to evaluate the animals' cardiac function. Macaques were sedated with ketamine and propofol and then were examined in the supine position, using a commercially available ultrasound system with a 5 MHz probe (Vivid-q, GE Healthcare, Horten, Norway). Apical four-chamber views were collected for baseline left ventricular ejection fraction (LVEF) measurement. Quantification of LVEF was performed by a qualified cardiologist according to the recommendation of the American Society of Echocardiography.
Telemetric EKG. EKG recordings were acquired from conscious, freely mobile animals using a Vmed Vetcheck telemetry system. Animals had tunneled subcutaneous EKG wires implanted, providing lead II tracings. Continuous telemetry was sent wirelessly to a dedicated laptop for all macaques with myocardial infarction with or without hESC-CM delivery on post-myocardial infarction days 1, 4, 7, 10, and 13 and post-intramyocardial injection days 3, 6, 9, 12, 15, 18, 21, 24, and 27 . All EKG traces were evaluated manually by a cardiologist (Y.-W.L.) using EKG Reviewer (Vmed), and the total number and duration of ventricular arrhythmias determined. A second cardiologist (B.C.) evaluated a subset of these telemetry tracings in a blinded manner, with excellent concordance (Supplementary Fig. 3c ). Premature ventricular complexes (PVCs) were defined as QRS complexes greater than 60 ms. Ventricular tachycardia (VT) was defined as a run of four or more PVCs with ventricular rate of more than 180 beats per min. Accelerated idioventricular rhythm (AIVR) was defined as four or more PVCs with a rate of less than 180 beats per min. VT or AIVR were considered sustained if the duration was greater than 30 s.
Histology and immunohistochemistry.
Histological studies were carried out as detailed previously 19, 25 with some adaptation. Paraformaldehyde-fixed macaque hearts were dissected to remove the atria and right ventricle before cross-sections were obtained by sectioning parallel to the short axis at 2.5 mm thickness on a commercial slicer (Berkel). Weights of the whole heart, left ventricle, and each slice were obtained before cutting heart slices to fit tissue cassettes. The tissue then was processed and embedded in paraffin, and fourmicrometer sections were cut for staining. For morphometry, infarct regions were identified by Picrosirius red staining; human grafts were identified by anti-human cardiac troponin I, stained using avidin-biotin reaction (ABC kits from VectorLabs) followed by chromogenic detection via diaminobenzidine (Sigmafast, Sigma Life Science). The slides were digitized using a Hamamatsu Nanozoomer whole slide scanner, and the images were viewed and exported with NDP software (NDP.view 2.6.13). Resulting images were imported into Image J software (version 1.51 k) where area of infarct and graft (region of interest or ROI) were measured. The mass of the ROI was determined by calculating the ratio of ROI area to total tissue area on the slide, and multiplying by the weight of the tissue the slide was cut from. The entire scar or graft was expressed as total weight or percent of LV mass.
For immunohistochemistry, we used the primary antibodies listed in Supplementary Table 2 . Primary antibodies then were followed either with fluorescent secondary antibodies (Alexa-conjugated, species-specific antibodies from Molecular Probes) or the avidin biotin reaction (ABC kits from VectorLabs), followed by chromogenic detection via diaminobenzidine (Sigmafast, Sigma Life Science). Immunofluorescent images were collected with either a Nikon A1Confocal System or a Nikon Ti-E inverted widefield microscope. For high-resolution confocal images, a 60× CFI Plan Apo Water immersion objective lens (NA 1.2) was used. 12-bit images were captured with the pinhole at 1 Airy Unit and field size at 1,024 × 1,024 pixels. For large field immunostained sections, a CFI Pan Apo lambda 4× objective (NA 0.2) was used on the widefield system. Grids of 14-bit Images were captured using a Photometrics CoolSnap HQ2 CCD camera and stitched with NIS Elements version 5.00 software. For figure preparation, images were exported into Photoshop CS3 (Adobe). If necessary, brightness and contrast were adjusted for the entire image and the image was cropped.
Histomorphometry. Infarct size was determined from whole-slide scans of picrosirius red-fast green stained tissue sections. Infarct size was calculated as Σ(block mass × infarct area/block area) and expressed as a percentage of the left ventricular mass.
Graft size was determined from whole-slide scans of sections stained with human-specific cTnT. Graft size was calculated as Σ(block mass × graft area/ block area) and expressed either as a percentage of the left ventricular mass or the infarct mass.
Vascular density was determined from photomicrographs of CD31-stained sections from the graft, scar, and remote (non-infarcted) myocardium obtained with a 40× objective. A defined-area grid was overlaid onto the image, and vascular profiles within a region of interest were counted. Vessels that crossed into multiple grid subunits were counted only once. Vascular density is expressed as the number of vessels/mm 2 .
Graft cardiomyocyte number was estimated from photomicrographs of sections stained with pericentriolar material-1 (PCM-1). Regions of interest shown to contain no host cardiomyocytes in adjacent sections were photographed with a 40× objective. A defined-area grid was overlaid onto the image, and PCM-1 + nuclear profiles with clear rings of perinuclear staining were counted. To determine the number of microscopic fields required, we performed a systematic downsampling study. Counting 42, 25, 10, and 5 fields yielded cardiomyocyte densities of 3,865, 3,848, 3,934, and 3,858 nuclei/mm 2 . Subsequent studies were done with five fields per heart. To calculate graft cardiomyocyte nuclear density on a volume basis, we made the assumption that the nuclei were isotropically packed, that is, that the densities in the XY, XZ, and YZ planes were equivalent. (This was supported by microscopic observation that linear nuclear densities in the X and Y dimensions were comparable.) Volume-based nuclear density was calculated as (nuclei/mm 2 ) 1.5 , yielding nuclei/mm 3 . Finally, because our grafts were relatively immature, we made the assumption that each cardiomyocyte was mononucleated, meaning that nuclear density = cardiomyocyte density. (Note that even in adult human myocardium, only 25% of cardiomyocytes have more than one nucleus 2 , so the impact of this assumption is modest.) Total graft number was determined as: In situ hybridization. Engrafted human cells were identified using in situ hybridization with a human-specific pan-centromeric genomic probe as previously reported 4 and used to validate human specific antibodies. In brief, the human-specific pan-centromeric probe was generated by modification of a protocol previously reported 7 that involves degenerate PCR with primers against human alpha satellite pan-centromeric repeat sequences. PCR was performed for 30 cycles: denaturation at 94 °C for 1 min; annealing at 45 °C for 1 min; extension at 72 °C for 1 min. We then labeled the PCR product with biotin (Biotin DecaLabel DNA kit, Thermo Scientific) to generate the in situ probe. The pan-centromeric probe was diluted in hybridization buffer (0.5× SSC, 10% dextran sulfate, 50% deionized formamide, 0.4 mg/mL salmon sperm DNA), heated to 80 °C to denature the DNA, applied to the slide and hybridized overnight at 37 °C. Subsequent detection after in situ hybridization used peroxidase-conjugated avidin (ABC kits from VectorLabs). For immunohistochemistry, the in situ probe was detected by Alexa Fluor 594 tyramide amplification (Molecular Probes).
PCR detection of human DNA. One of the hESC-CM-treated animals had a renal tumor identified during necropsy. Human-and macaque-specific primers were used to determine that the tumor was not human tissue. Genomic DNA was isolated from adjacent slices (with respect to pan-centromeric probe section) using a Qiagen DNeasy tissue kit and 250 ng of input gDNA per sample was used for PCR. Human (HS) and macaque (MN) gDNA was used as controls.
To detect human DNA, we made primers targeting human mitochondria: forward primer 5′-CACCGGCGCAGTCATTCTCATA-3′ and reverse primer 5′-GAGTCCTGTAAGTAGGAGA-3′. PCR profile: 95 °C/1 min, 59 °C/1 min, 72 °C/1 min for 40 cycles, product size 267 bp. Human-specific primers detect a 249 bp region on human mitochondria DNA (11680-11929; MF992925.1).
For macaque-specific PCR, we developed primers targeting chromosome-3: forward primer 5′-CAGTTGGCTGTTCAGTATAGCGAT-3′ and reverse primer 5′-CTTCAGAGTATGTGACATAGGT-3′. PCR profile: 95 °C/1 min, 55 °C/1 min, 72 °C/1 min for 40 cycles, product size 150 bp. Macaque-specific 1 nature research | reporting summary 
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Software and code
Policy information about availability of computer code Data collection • Echocardiography was done using a commercially available ultrasound system with a 5 MHz probe (Vivid-q, GE Healthcare, Horten, Norway). • EKG recordings were acquired using a Vmed Vetcheck telemetry system. • Hamamatsu Nanozoomer whole slide scanner was used to get the whole slide images. The images from the scanner is viewed with NDP software (NDP.view 2.6.13).
• Microscopic histological images were taken using NIS Elements Version 5.00. • Activation mapping was performed using the CARTO III system with either a 7-French NaviStar B-or D-curve catheter or a 7-French Dcurve PENTARAY catheter (Biosense Webster Inc, South Diamond Bar, CA, USA ) Data analysis • Statistical analysis was performed using Graphpad Prism software version 7. • The images from Hamamatsu Nanozoomer whole slide scanner is viewed with NDP software (NDP.view 2.6.13). • Image J (version 1.51s) was used to view and adjust brightness/contrast of the histological images. • Histological images were taken using NIS Elements Version 5.00. • Cardiac MRI analysis was done using Intellispace Portal version 9.0, Philips, Best, Netherlands.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. 
Validation
Each antibody was validated using established positive and negative controls and titered for an optimal signal:noise ratio. Both human and macaque monkey samples were used to establish which antibodies to use and the specifics of their immunostaining assays.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s)
We used RUES2 (Rockefeller University) and H7 (University of Wisconsin/WiCell) human embryonic stem cell lines.
Authentication
We used a commercial short tandem repeat assay and matched our results against published standards for both cell lines.
Mycoplasma contamination
All cells were routinely tested for mycoplasma and were negative.
Commonly misidentified lines (See ICLAC register)
Neither of our cell lines are on the ICLAC registry.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
The subjects in our study were pigtailed macaques, Macaca nemestrina. They were provided by the Washington National Primate Research Center. Both male and female animals were studied. Specific details on gender, age, weight are pasted below. They also can be found in Table 1 of the manuscript in a more legible format.
Control P14 M 6y 10mo 12.6 P15 F 9y 7mo 11.7 P18 F 10y 9mo 11.4 P20 F 6y 0mo 10.6 Mean 8 11.6 SEM 1 0.4 hESC-CM P22 F 15y 7mo 7.0 P23 F 11y 6mo 10.7 P24 F 12y 2mo 9.5 P25 F 6y 7mo 5.2 P39 F 14y 6 mo 9.2 Mean 11 8.6 SEM 2 0.9
Wild animals
The study did not involve wild animals.
Field-collected samples
The study did not involve samples collected from the field.
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